This video is available only for registered users. (Cancel and go back to Homepage)

Register FREE now!
Click Here »

As registered user you will:
  • a) Get full access to videos
  • b) Receive monthly newsletter with stock information
Already registered?
Email adress:
Mon, 27th Apr 2015
Graham Lumsden, chief executive of Motif Bio (LON:MTFB), discusses the potential size of the...
Fri, 24th Apr 2015
Summary of Events
RANsquawk Weekly Wrap - 24th April 2015
Mon, 20th Apr 2015
Summary of Events
Week Ahead - 20th April 2015
Fri, 17th Apr 2015
Summary of Events
Weekly Wrap - 17th April 2015
Tue, 14th Apr 2015
Summary of Events
PREVIEW: ECB Rate Decision - 15th April 2015
Mon, 13th Apr 2015
Summary of Events
Week Ahead - 13th April 2015
Fri, 10th Apr 2015
Summary of Events
Weekly Wrap - 10th April 2015
Mon, 27th Apr 2015
Graham Lumsden, chief executive of Motif Bio (LON:MTFB), discusses the potential size of the market for its lead antiobiotic candidate, iclaprim. Lumdsen explains that the company plans to fund its phase III trials through grants, partnerships and possibly through a capital raise, but the focus is on ‘not diluting shareholders’, he stresses. The group’s chief executive says there is plenty of newsflow to come, with possible approval for these trials from the US and Europe via the FDA and the EMA respectively. The company anticipates that iclaprim ‘could be ready for commercialisation within approximately 36 months’.
Motif Bio chief on vast market opportunity for lead drug
Mon, 27th Apr 2015
Mark Jones, chief executive of Alecto Minerals (LON:ALO), tells Proactive Investors the acquisition of Kerboulé has been vindicated by today’s independent resource estimate for the gold project in Burkina Faso. The resource, compiled by Wardell Armstrong, comes in at 6.2 million tonnes, grading at 1.16 grams per tonne (g/t) gold for 230,758 ounces of gold, at a cut-off 0.5 g/t. Jones says the company will ‘continue to establish and look for quality portfolio assets as we understand who out there would like to access this sort of ground in a potential joint venture scenario’.
Alecto Minerals CEO says resources estimate proves project acquisition was a good one
Mon, 27th Apr 2015
Richard Wolanski, finance director of Avation plc (LON:AVAP), says the passenger aircraft leasing group is well placed to benefit from the fast pace of growth in the Asia-Pacific airline industry. He adds that the company also has high hopes for the European sector too and has just unveiled a four-aircraft deal with Flybe over the next 12 months. Wolanski also explains how the company, whose share price has risen 27% over the past year, is managing to outperform an already fast-growing market. Today, the company revealed it is to launch a medium-term note programme to reduce its reliance on placings.
Avation finance director says company is well placed to reap rewards of Asia-Pacific growth
Mon, 27th Apr 2015
Ken Kroeger, chief executive of Seeing Machines (LON:SEE), discusses the potential of the company’s fatigue-monitoring technology in the commercial market. Today, the AIM-listed group launched its Fleet in-cab accident avoidance product for trucks and buses into the US market. Using the company’s cutting edge DSS technology that tracks the eyes and face for signs of fatigue, the unit triggers in an alarm and sends seat vibrations at the first sign of a driver losing concentration. Until now, Seeing Machines’ main source of business has been in the mining industry.
Seeing Machines CEO on potential of commercial launch
Fri, 24th Apr 2015
Matthew Walls, chief executive of Epistem (LON:EHP), says distribution of its handheld TB diagnostic device in India paves the way for other distributor-based deals globally. Walls tells Proactive Investors the test market for TB will be worth US$2bln by 2020, and the biotechnology company’s signature Genedrive tool lends itself to testing all bacterial, viral, fungal and somatic mutations of the body. Described as 'breakthrough next generation technology' Genedrive is gathering more commercial exposure and Walls says more funds may be required over the next few months to accelerate the device’s push into the global marketplace.
Epistem accelerating global push of unique TB diagnostic device
Fri, 24th Apr 2015
Peter George, chief executive of Clinigen (LON:CLIN), says the £225mln acquisition of competitor Idis gives it access to the US$2.2bln ethical unlicensed medicine market. Synergy savings of £2.5mln have been identified in the deal which makes the specialty pharma company the global leader in unlicensed medicines. George tells Proactive Investors profit will be driven through the gross profit line much faster than synergy savings. “This is about a growth plan not a cost savings plan. We want to hit the ground running and take the market by storm.” The deal achieves the second of Clinigen’s four strategic goals which include becoming global leader in both clinical trials supply and unlicensed medicines. George says Clinigen wants to grow its portfolio from five to ten products and improve its global footprint by looking at the Southern hemisphere.
Clinigen now global leader in unlicensed medicines after Idis deal
Thu, 23rd Apr 2015
Paul Johnson, executive director at Metal Tiger (LON:MTR), explains that the funds raised will help the company to accelerate its plans. Today, the natural resources investor has raised £175,000 through a strategic share sale at 0.875p each. The proceeds will allow the AIM-quoted company to expand further its own investing activities particularly within its Direct Project division. ‘Watch this space because we like to tell the market what we’re doing but we do have lots of ideas and we’re looking forward to the next few weeks and months,’ Johnson says.
Metal Tiger’s Johnson says cash enables acceleration
Thu, 23rd Apr 2015
Adam Bond, chief executive of AFC Energy (LON:AFC), tells Proactive Investors the latest fuel cell deal unveiled today in Dubai is a great start towards the group’s goal of having 1 gigawatt of capacity under development by the end of 2020. The company has just announced that it has signed a memorandum of understanding (MoU) with Dubai Carbon for around 300 megawatts of its fuel cells in Dubai. Bond explains the role water can play in the company’s ‘value proposition’ and insists by the time the cells are deployed, the company will have a ‘fully commercially compliant project and technology’.
AFC Energy chief: Dubai deal is ‘great start’ towards 1 GW target
Thu, 23rd Apr 2015
Kevin Foo, the chairman of Victoria Oil & Gas (LON:VOG), believes the company has turned the corner now it has switched on the second of two power stations it has built recently in Douala in Cameroon. The stations, Logbaba and Bassa, are now supplying 50 megawatts of electricity to the local grid using gas supplied from Victoria Oil & Gas’s 60%-owned Logbaba field. Foo says he is confident the group can meet the target gas production of 10.5 million standard cubic feet for this year. He would like to see that double again the following year.
Victoria Oil & Gas has ‘turned the corner’ – chairman
Thu, 23rd Apr 2015
Ian Harebottle, the chief executive of Gemfields (LON:GEM), says he is encouraged by the demand, adding that retail giants such as Walmart are interested in the lower quality gemstones. Virtually all of the rubies on offer at the latest auction in Jaipur were snapped up, generating US$16.1mln in revenue. The third auction of rubies from Gemfields’ 75%-owned asset at Montepuez in Mozambique was predominantly of lower quality material. The company said that 3.99mln of the 4.03mln of carats on offer were bought at an average value of US$4.03 a carat.
Gemfields CEO encouraged by demand for lower quality rubies
Thu, 23rd Apr 2015
CloudTag’s (LON:CTAG) new chief technology officer Alon Moss explains that the ‘visionary approach’ is what attracted him to the AIM-listed company. Moss tells Proactive Investors why he is so excited about the rapidly growing ‘wearables’ market and says he is a ‘new product specialist’ with a proven track record of developing new products. More specifically, he has created products for the likes of NASDAQ-listed Comverse, which have generated revenues of over US$200mln. ‘As devices get smaller, lighter, more energy efficient, I think this market will just grow – the potential for applications is very large,’ Moss says.
New CloudTag technology chief outlines vision for company
Wed, 22nd Apr 2015
Crispin Simon, chief executive of Rex Bionics (LON:RXB), talks to Proactive Investors about the launch of the company’s robotic mobility product in Hong Kong as its sales push picks up speed. The company has teamed up with Deltason Medical to launch its REX mobility robot for people with spinal injury into markets in Hong Kong and China. Deltason, a distributor of medical rehab aids, will look to place the mobility enhancing REX units with neuro-rehabilitation clinics as well as for personal use in homes.
Rex Bionics CEO talks commercialisation, Hong Kong and the exit strategy